Prescription Potassium Chloride Extended-Release Capsules Recalled for Manufacturing Deviations
Glenmark Pharmaceuticals is recalling Potassium Chloride Extended-Release Capsules nationwide due to manufacturing practice deviations. The voluntary recall affects multiple lot numbers, with no reported illnesses or injuries.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II voluntary precautionary recall with no reported illnesses or injuries. The hazard is a CGMP deviation—a manufacturing quality issue without reported specific harm. Per the rubric, voluntary precautionary recalls with no reported illness and theoretical hazards are classified as Moderate.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA, is recalling Potassium Chloride Extended-Release Capsules, USP, in 500-count bottles containing 750 mg (10 mEq K). The recall affects multiple lot numbers distributed nationwide, with expiration dates ranging from December 2024 through September 2025.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations discovered during manufacturing. No illnesses or injuries related to this product have been reported as of the recall notice date.
The product is a prescription medication (NDC 68462-357-05) manufactured by Glenmark Pharmaceuticals Ltd. in Pithampur, Madhya Pradesh, India, and manufactured for Glenmark Pharmaceuticals Inc. in Mahwah, New Jersey. This is a voluntary recall initiated by the firm, with the recall ongoing as of the report date of July 24, 2024.
The recalled product
- Product
- POTASSIUM CHLORIDE (POTASSIUM CHLORIDE)
- Brand
- POTASSIUM CHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription Drug
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: 17230186
- 17230192
- 17230213
- 17230278
- 17230399
- Exp Dec-31-24
- 17230406
- 17230412
- 17230427
- 17230444
- 17230453
- 17230495
- Exp Jan-31-25
- 17230574
- 17230585
- 17230608
- 17230629
- Exp Feb-28-25
- 17230883
- 17230921
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · POTASSIUM CHLORIDE
- SeverePotassium Chloride Injection Recalled Nationwide for Mislabeled Strength
FDA (Drugs) · 2025-11-26
- CriticalPotassium Chloride Injection Recalled for Incorrect Strength on Overwrap Label
FDA (Drugs) · 2025-11-26
- SeverePotassium Chloride Injection Strength Mislabeled on Packaging Overwrap
FDA (Drugs) · 2025-03-19
- SeverePotassium Chloride Injection Recalled: Overwrap Labeling Shows Incorrect Strength
FDA (Drugs) · 2025-03-19
- HighPotassium Chloride Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2025-02-12
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27